KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) FCF Margin (2016 - 2025)

Supernus Pharmaceuticals has reported FCF Margin over the past 15 years, most recently at 9.19% for Q4 2025.

  • Quarterly FCF Margin fell 1619.0% to 9.19% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 6.4% through Dec 2025, down 1947.0% year-over-year, with the annual reading at 6.4% for FY2025, 1947.0% down from the prior year.
  • FCF Margin was 9.19% for Q4 2025 at Supernus Pharmaceuticals, up from 32.17% in the prior quarter.
  • Over five years, FCF Margin peaked at 41.8% in Q2 2022 and troughed at 32.17% in Q3 2025.
  • The 5-year median for FCF Margin is 24.3% (2023), against an average of 18.05%.
  • Year-over-year, FCF Margin soared 3517bps in 2024 and then crashed -6252bps in 2025.
  • A 5-year view of FCF Margin shows it stood at 30.66% in 2021, then crashed by -46bps to 16.57% in 2022, then soared by 65bps to 27.38% in 2023, then decreased by -7bps to 25.38% in 2024, then crashed by -64bps to 9.19% in 2025.
  • Per Business Quant, the three most recent readings for SUPN's FCF Margin are 9.19% (Q4 2025), 32.17% (Q3 2025), and 35.1% (Q2 2025).